...
首页> 外文期刊>Annals of surgical oncology >A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
【24h】

A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.

机译:对最初无法切除的结直肠肝转移患者缩小全身化疗和抢救肝脏手术的临床反应和生存结果的系统评价。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Selected patients with unresectable colorectal liver metastases (CLM) may be rendered resectable after systemic chemotherapy. We reviewed the evidence of downsizing systemic chemotherapy followed by rescue liver surgery in patients with initially unresectable CLM.Literature search of databases (Medline and PubMed) to identify published studies of neoadjuvant chemotherapy followed by liver resection in patients with initially unresectable CLM was undertaken and focused on response rate of chemotherapy and survival outcomes.Ten observational studies were reviewed. A total of 1,886 patients with initially unresectable CLM underwent systemic chemotherapy. An objective response was observed in 64% (range, 43-79%) of patients after systemic chemotherapy. Of these, 22.5% underwent macroscopically curative liver resection. Median overall survival was 45 (range, 36-60) months with 19% of patients alive and recurrence-free.Current evidence suggests that downsizing systematic chemotherapy followed by rescue liver resection is safe and effective for selected patients with initially unresectable CLM. Further studies are required to examine response rates and secondary resectability using new targeted molecular therapy-based regimens.
机译:某些无法切除的结直肠肝转移(CLM)患者可能会在全身化疗后被切除。我们回顾了原发性不能切除的CLM患者的全身化疗方案缩小,随后进行抢救性肝手术的证据,并进行了文献检索(Medline和PubMed),以鉴定已发表的新辅助化疗和原发性不能切除的CLM患者肝切除的研究。化疗的反应率和生存结果。回顾十项观察性研究。总共1,886例最初无法切除的CLM患者接受了全身化学疗法。全身化疗后64%(43-79%)的患者观察到客观反应。其中22.5%接受了宏观根治性肝切除。中位总生存期为45(36-60个月),其中19%的患者活着且无复发。目前的证据表明,对于最初无法切除的CLM的部分患者,系统化化疗的缩小规模和急诊肝切除术是安全有效的。需要使用基于靶向分子疗法的新方案来研究缓解率和继发可切除性的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号